CYCD6-1 Antibody

What is CYCD6-1 and why is it important for developmental biology research?

CYCD6-1 (also written as CYCD6;1) is a D-type cyclin in Arabidopsis thaliana that plays a specific role in formative cell divisions, particularly in the cortex endodermis initial (CEI) daughter cells in the root meristem. Unlike other cyclins involved in general proliferative divisions, CYCD6-1 is specifically required for asymmetric, formative divisions needed for proper ground tissue patterning .

The significance of CYCD6-1 lies in its position as a direct molecular link between developmental regulators (the SHORTROOT/SCARECROW transcriptional network) and the cell cycle machinery . In cycd6;1 mutant seedlings, CEI-daughter cells show significantly fewer formative divisions, confirming its specialized role in development rather than general cell proliferation . This makes CYCD6-1 antibodies particularly valuable for studying the molecular mechanisms controlling tissue patterning and cell fate determination.

What is the expression pattern of CYCD6-1 in plant tissues?

CYCD6-1 exhibits a highly specific expression pattern that correlates with its specialized function:

• CEI/CEI-daughter cells in the root meristem, where it's rarely detected in all eight CEI/CEI-daughter cells simultaneously, indicating that formative divisions are not tightly synchronized

• Embryonic CEI-daughter cells during early heart and torpedo embryo stages

• A subset of endodermal cells that undergo formative divisions to form middle cortex

• Lateral root primordia in older plants

• Pericycle and phloem cells, which also undergo formative divisions

This restricted expression pattern distinguishes CYCD6-1 from other D-type cyclins and makes it an excellent marker for specific formative divisions within the SHR and/or SCR functional domains .

How does CYCD6-1 differ functionally from other D-type cyclins?

CYCD6-1 possesses several unique characteristics that distinguish it from other D-type cyclins:

• Functional specificity: CYCD6-1 is specifically involved in formative divisions rather than proliferative cell divisions, unlike CYCD2;1 and CYCD5;1

• Regulatory control: It is directly regulated by the SHR/SCR transcriptional network, with both proteins binding to its promoter region approximately 1 kb upstream

• Temporal expression: CYCD6-1 is expressed coincident with the onset of formative divisions (approximately 6 hours after SHR/SCR induction)

• Phenotypic effects: Mutation in CYCD6-1 affects only a small number of formative divisions at specific developmental stages

Single mutations in CYCD2;1 and CYCD5;1 do not affect CEI-daughter divisions, and double mutants (cycd6;1cycd2;1 and cycd6;1cycd5;1) show phenotypes similar to cycd6;1 alone, suggesting higher levels of functional redundancy among D-type cyclins for most divisions .

How can CYCD6-1 antibodies be used to study the temporal dynamics of formative cell divisions?

To investigate the temporal dynamics of formative cell divisions using CYCD6-1 antibodies, researchers can implement several sophisticated approaches:

• Time-course immunolocalization with SHR/SCR-inducible systems:

  • Use pSHR::SHR:GR or pSCR::SCR:GR inducible lines to precisely control the activation of the regulatory pathway

  • Collect samples at specific time points after induction (1h, 6h, 12h, 24h)

  • Perform immunostaining with CYCD6-1 antibodies to track protein accumulation

  • Correlate CYCD6-1 protein levels with the onset of formative divisions

• Dual-labeling experiments:

  • Co-immunolocalize CYCD6-1 with cell cycle phase markers

  • Combine with EdU labeling to identify S-phase cells

  • Analyze the precise timing of CYCD6-1 accumulation relative to division events

This approach would reveal that CYCD6-1 accumulation coincides with formative divisions approximately 6 hours after SHR/SCR induction, matching the gene expression data showing that cell-cycle genes are overrepresented in clusters activated 6 hours after induction .

What methodological approaches are needed to differentiate between CYCD6-1 and other related cyclin proteins?

Differentiating CYCD6-1 from other related cyclins requires careful methodological considerations:

• Epitope selection strategy:

  • Generate antibodies against unique N-terminal or C-terminal regions of CYCD6-1

  • Avoid the highly conserved cyclin box domain to minimize cross-reactivity

  • Use peptide sequences unique to CYCD6-1 compared to CYCD2;1 and CYCD5;1

• Rigorous validation protocol:

  • Test antibody specificity against wild-type and cycd6;1 mutant tissues (GK-368E07 line)

  • Perform western blotting to confirm a single band of the expected size

  • Validate immunostaining patterns against pCYCD6;1::GFP reporter expression

  • Conduct peptide competition assays to confirm specificity

• Comparative analysis:

  • Compare immunostaining patterns with known CYCD6-1 expression domains (CEI/CEI-daughter cells)

  • Contrast with expression patterns of other D-type cyclins determined by their respective reporters

This methodological rigor is essential because D-type cyclins have significant sequence homology, particularly in the cyclin box domain, making antibody specificity a critical concern for reliable experimental results.

How can ChIP experiments with CYCD6-1 antibodies provide insights into the regulatory network controlling formative divisions?

While CYCD6-1 itself is a target of transcription factors rather than a DNA-binding protein, ChIP experiments with CYCD6-1 antibodies can still provide valuable insights through these methodological approaches:

• Sequential ChIP (ChIP-reChIP):

  • First ChIP with SHR or SCR antibodies

  • Second ChIP with CYCD6-1 antibodies

  • Identify genomic regions where SHR/SCR and CYCD6-1 co-localize

  • This approach would build on the finding that SHR and SCR directly bind the CYCD6;1 promoter

• Protein complex analysis:

  • Use CYCD6-1 antibodies to immunoprecipitate chromatin-associated complexes

  • Identify cyclin-dependent kinase partners and other associated proteins

  • Map the protein interaction network surrounding CYCD6-1 at chromatin

• Genome-wide approaches:

  • Compare ChIP-seq data for CYCD6-1-associated proteins with the 266 direct targets of SHR

  • Identify additional regulatory connections beyond the six SHR direct target genes in the SCR cluster

This approach would extend our understanding beyond the known binding of SHR and SCR to the CYCD6;1 promoter approximately 1 kb upstream, as demonstrated by ChIP-qPCR .

What is the optimal protocol for immunohistochemical detection of CYCD6-1 in root sections?

For optimal immunohistochemical detection of CYCD6-1 in root tissues, the following methodological approach is recommended:

• Sample preparation:

  • Fix 5-day-old Arabidopsis seedlings in 4% paraformaldehyde in PBS buffer

  • For whole-mount immunolocalization, digest cell walls with enzymes (driselase, cellulase, pectolyase)

  • Permeabilize with 0.5% Triton X-100

• Immunostaining procedure:

  • Block with 3% BSA in PBS for 1 hour

  • Incubate with primary CYCD6-1 antibody (1:200-1:500 dilution) overnight at 4°C

  • Wash thoroughly with PBS + 0.1% Tween-20

  • Incubate with fluorophore-conjugated secondary antibody

  • Counterstain with 10 μM propidium iodide for cell wall visualization

• Critical controls:

  • Include cycd6;1 mutant tissues (GK-368E07) as negative control

  • Use pCYCD6;1::GFP transgenic lines as positive reference for expression pattern

  • Perform peptide competition controls

• Imaging recommendations:

  • Use confocal microscopy with Z-stack acquisition

  • Generate both longitudinal and transverse optical sections

  • For transverse sections, take images just above the quiescent center to visualize CEI-daughter cells

This protocol should reveal CYCD6-1 expression specifically in CEI/CEI-daughter cells, matching the pattern observed with the pCYCD6;1::GFP transcriptional reporter .

How can CYCD6-1 antibodies be used in co-immunoprecipitation studies to identify interaction partners?

For effective co-immunoprecipitation studies with CYCD6-1 antibodies:

• Sample preparation:

  • Use mild lysis conditions to preserve protein-protein interactions

  • Include phosphatase inhibitors to maintain phosphorylation-dependent interactions

  • Enrich for root tip tissue where CYCD6-1 is expressed

  • Consider crosslinking approaches for transient interactions

• Immunoprecipitation methodology:

  • Pre-clear lysates with protein A/G beads

  • Use affinity-purified CYCD6-1 antibodies

  • Include extended incubation times (overnight) at 4°C

  • Perform stringent washing to reduce non-specific binding

• Controls and validation:

  • Include IgG isotype control immunoprecipitation

  • Perform reciprocal co-IP with antibodies against suspected partners (CDKs)

  • Use cycd6;1 mutant tissue as negative control

Expected interaction partners for CYCD6-1 would include cyclin-dependent kinases, particularly CDKB2;1 and CDKB2;2, which have been shown to function in the same pathway for formative divisions . Other potential interactors include SHR and SCR transcription factors, which directly regulate CYCD6;1 expression .

What are the best approaches for using CYCD6-1 antibodies in western blotting applications?

For effective western blotting with CYCD6-1 antibodies:

• Sample preparation optimization:

  • Enrich for tissues with known CYCD6-1 expression (root tips, specifically CEI/CEI-daughter cells)

  • Use protein extraction buffer with protease inhibitors

  • Consider immunoprecipitation to concentrate low-abundance CYCD6-1 protein

  • Include phosphatase inhibitors to preserve phosphorylation states

• Western blotting procedure:

  • Separate proteins on 10-12% SDS-PAGE gels

  • Transfer to PVDF membrane (preferred for low-abundance proteins)

  • Block with 5% non-fat dry milk or BSA in TBST

  • Incubate with primary CYCD6-1 antibody (1:500-1:1000) overnight at 4°C

  • Use high-sensitivity chemiluminescent detection systems

• Controls and validation:

  • Include recombinant CYCD6-1 protein as positive control

  • Use cycd6;1 mutant tissue lysate as negative control

  • Compare expression in wild-type versus J0571-UAS::CYCD6;1:YFP overexpression lines

• Developmental staging recommendations:

  • Compare CYCD6-1 levels across different developmental stages

  • Analyze protein abundance in inducible SHR/SCR systems at timepoints corresponding to the onset of formative divisions (6 hours post-induction)

This approach would allow quantitative assessment of CYCD6-1 protein levels that could be correlated with the formative division phenotypes observed in genetic studies .

What are common challenges in CYCD6-1 antibody applications and how can they be addressed?

Researchers working with CYCD6-1 antibodies may encounter several challenges:

• Low signal detection:

  • Challenge: CYCD6-1 is expressed in a very restricted domain (CEI/CEI-daughter cells) and not all express the protein simultaneously

  • Solution: Use signal amplification methods like tyramide signal amplification

  • Solution: Enrich for CYCD6-1-expressing cells using laser capture microdissection

  • Solution: Increase antibody concentration and extended incubation times

• Specificity concerns:

  • Challenge: Cross-reactivity with other D-type cyclins (CYCD2;1, CYCD5;1)

  • Solution: Pre-absorb antibody with recombinant related cyclins

  • Solution: Validate specificity using cycd6;1 mutant tissue as negative control

  • Solution: Compare staining pattern with pCYCD6;1::GFP expression

• Temporal variability:

  • Challenge: CYCD6-1 expression is not synchronized in all CEI/CEI-daughter cells

  • Solution: Analyze larger sample sizes to capture cells at different stages

  • Solution: Use time-course experiments with SHR/SCR inducible systems

  • Solution: Complement with cell-cycle phase markers

• Developmental stage differences:

  • Challenge: CYCD6-1 expression changes through development (embryonic vs. post-embryonic)

  • Solution: Clearly define developmental stages in experimental design

  • Solution: Compare expression at specific stages (early heart, torpedo, mature embryo)

These methodological approaches address the specific biological properties of CYCD6-1, including its restricted expression pattern and specialized function in formative divisions.

How can researchers validate CYCD6-1 antibody specificity in plant tissues?

A comprehensive validation strategy for CYCD6-1 antibodies should include:

• Genetic validation:

  • Test antibody reactivity in wild-type versus cycd6;1 knockout line (GK-368E07)

  • Compare staining patterns in overexpression lines (J0571-UAS::CYCD6;1:YFP)

  • Evaluate antibody performance in shr and scr mutants, where CYCD6;1 expression should be reduced

• Expression pattern validation:

  • Compare immunostaining patterns with pCYCD6;1::GFP reporter expression

  • Verify localization in expected tissues: CEI/CEI-daughter cells, embryonic CEI-daughter cells, subset of endodermal cells, lateral root primordia

  • Confirm absence in tissues where expression is not expected

• Biochemical validation:

  • Perform western blot analysis to confirm single band of expected size

  • Conduct peptide competition assays with immunizing peptide

  • Test reactivity against recombinant CYCD6-1 protein

• Functional correlation:

  • Correlate antibody staining with formative division phenotypes

  • Verify increased signal in cells actively undergoing formative divisions

  • Compare timing of protein detection with known expression dynamics after SHR/SCR induction (approximately 6 hours)

This rigorous validation approach ensures that experimental results truly reflect CYCD6-1 biology rather than artifacts or cross-reactivity.

What experimental controls are essential when working with CYCD6-1 antibodies?

Essential experimental controls for CYCD6-1 antibody applications include:

• Genetic controls:

  • cycd6;1 mutant tissue (GK-368E07) as negative control

  • J0571-UAS::CYCD6;1:YFP overexpression line as positive control

  • shr-2 and scr-4 mutants as regulatory pathway controls

• Technical controls:

  • Omission of primary antibody to assess background from secondary antibody

  • Isotype control antibody to evaluate non-specific binding

  • Peptide competition/preabsorption control

  • Dilution series to determine optimal antibody concentration

• Expression pattern controls:

  • pCYCD6;1::GFP reporter line to verify expression domains

  • Co-staining with markers for CEI/CEI-daughter cells

  • Developmental stage-matched samples

• Application-specific controls:

  • For western blotting: Loading controls and molecular weight markers

  • For immunoprecipitation: Input sample, IgG control, and bead-only control

  • For ChIP: Input DNA, non-specific genomic regions, and known target regions

These controls address both the technical aspects of antibody applications and the biological specificity of CYCD6-1 expression and function in plant development.

How does CYCD6-1 function compare with other cell cycle regulators in the control of formative divisions?

Comparative analysis reveals CYCD6-1's unique position among cell cycle regulators:

• Regulatory hierarchy:

  • CYCD6-1 is directly regulated by SHR and SCR transcription factors

  • CYCD6-1 functions upstream of CDKB2;1 and CDKB2;2 in controlling formative divisions

  • Together, these components form a specialized regulatory module for asymmetric divisions

• Functional specificity:

  • CYCD6-1: Specifically involved in formative divisions in ground tissue

  • CDKB2;1/CDKB2;2: Function in the same pathway as CYCD6-1 for formative divisions

  • Other D-type cyclins (CYCD2;1, CYCD5;1): Function primarily in proliferative divisions

• Phenotypic effects:

  • cycd6;1 mutants show significantly fewer formative divisions in CEI-daughter cells

  • Ectopic expression of CYCD6-1 or CDKB2;1 can partially complement the shr formative division phenotype (27% and 25% of plants showed divisions, respectively)

  • This indicates both genes have important but not sufficient roles downstream of SHR

• Temporal expression:

  • CYCD6-1 is expressed coincident with the onset of formative divisions (6 hours after SHR/SCR induction)

  • This timing correlates with enrichment of cell-cycle progression and CDK activity gene ontology categories in genes activated 6 hours after induction

This comparative analysis demonstrates that CYCD6-1 represents a specialized cell-cycle component dedicated to formative rather than proliferative divisions.

How can multiplexed immunostaining with CYCD6-1 and other markers advance our understanding of formative divisions?

Multiplexed immunostaining approaches offer powerful insights into formative division mechanisms:

• Co-localization with regulatory factors:

  • CYCD6-1 + SHR/SCR: Visualize the spatial relationship between transcription factors and their target

  • CYCD6-1 + CDKB2;1/CDKB2;2: Examine the coordination between cyclin and its kinase partners

  • CYCD6-1 + cell fate markers: Link division timing with cell identity specification

• Cell cycle phase coordination:

  • CYCD6-1 + S-phase markers (EdU, PCNA): Determine when during the cell cycle CYCD6-1 accumulates

  • CYCD6-1 + M-phase markers (phospho-histone H3): Correlate CYCD6-1 levels with mitotic entry

  • CYCD6-1 + cytokinesis markers (KNOLLE/SYP111): Analyze the relationship between CYCD6-1 and completion of division

• Developmental timing analysis:

  • Time-course experiments with SHR/SCR inducible systems

  • Track protein accumulation patterns over developmental stages

  • Correlate with formation of middle cortex and lateral root initiation

This multiplexed approach would reveal that CYCD6-1 accumulation precedes and is required for the formative divisions in CEI-daughter cells, providing a mechanistic understanding of how developmental regulators control specific cell division events.

What can be learned from comparing wild-type and mutant phenotypes using CYCD6-1 antibodies?

Comparative phenotypic analysis using CYCD6-1 antibodies can reveal:

• Developmental compensation mechanisms:

  • In cycd6;1 mutants, CEI-daughter cells show fewer periclinal divisions initially, but by the mature embryo stage, the difference becomes less pronounced

  • This suggests compensatory mechanisms exist, potentially involving other D-type cyclins

• Tissue-specific requirements:

  • CYCD6-1 is required for normal middle cortex formation (52% in wild-type vs. 12% in cycd6;1)

  • The protein is also involved in formative divisions during lateral root development

  • Different tissues may have varying dependencies on CYCD6-1 function

• Functional redundancy:

  • Single cycd6;1 mutants show incomplete penetrance of the formative division phenotype

  • Double mutants (cycd6;1cycd2;1 and cycd6;1cycd5;1) are not significantly different from cycd6;1

  • This suggests higher-level redundancy involving other CYCD genes

• Regulatory network insights:

  • Ectopic expression of CYCD6-1 in shr mutant ground tissue can partially rescue the formative division defect (27% of plants)

  • This indicates CYCD6-1 functions downstream of SHR but additional factors are involved

This comparative approach provides a nuanced understanding of CYCD6-1's role within the broader context of developmental regulation and cell cycle control, revealing both its specific functions and its integration within redundant regulatory networks.